Sutro Biopharma (STRO)
Develops site-specific and dual-payload antibody-drug conjugates for oncology using cell-free protein synthesis.
Something off on this page? Send us feedback.
Develops clinical-stage oncology ADCs, including site-specific and dual-payload formats. Its XpressCF and XpressCF+ platforms combine cell-free protein synthesis with site-specific conjugation.
Develops clinical-stage oncology antibody-drug conjugates, or ADCs, designed around site-specific and novel formats. XpressCF is its integrated cell-free protein-synthesis platform, while XpressCF+ adds the site-specific conjugation platform used to design those formats, including dual-payload ADCs.
The post-review portfolio centers on wholly owned next-generation exatecan and dual-payload ADC programs, beginning with STRO-004. Research-and-development collaborations are also part of the operating model, while the company sought a partner for its deprioritized late-stage program.
Based in South San Francisco, the company reduced its internal operating footprint through 2025 restructuring. It exited its internal GMP manufacturing facility at year-end and externalized cell-free manufacturing to partners.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $164.3M · Total debt $10.8M · Total assets $194.5M · Shareholders' equity −$103.3M
- Revenue
- $9.8M
- Operating income
- −$29.9M
- Net income
- −$38.5M
No dividends on record.
| Institutions72 holders · as of Mar 31, 2026 | 85.01% | 14.10M shares | |
| Insiders11 holders · as of Jun 2, 2026 | 0.75% | 124.3K shares | |
| Otherremainder | 14.24% | 2.36M shares |
16.58M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (16.58M in the company's Sep 3, 2026 report, 9.68M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
BVF Inc/ILInstitution | 7.55% | 1.25M | 13Fas of Mar 31, 2026 |
Affinity Asset Advisors, LLCInstitution | 6.45% | 1.07M | 13Fas of Mar 31, 2026 |
Samsara Biocapital, LLCInstitution | 6.41% | 1.06M | 13Fas of Mar 31, 2026 |
Kynam Capital Management, LPInstitution | 5.26% | 872,558 | 13Fas of Mar 31, 2026 |
Orbimed Advisors LLCInstitution | 4.83% | 801,144 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Oct 15, 2025 | David Pauling | officer: Chief Admin. Ofcr. & GC | +12,504 | $0.7992 |
| Oct 15, 2025 | Connie Matsui | director | +50,000 | $0.7990 |
| Oct 15, 2025 | Jane Chung | director, officer: Chief Executive Officer | +12,500 | $0.8009 |
| Oct 15, 2025 | Gregory K. Chow | officer: CFO | +19,750 | $0.8100 |
| Oct 15, 2025 | Hans-Peter Gerber | officer: CHIEF SCIENTIFIC OFFICER | +17,000 | $0.8004 |
- Pfizer
TIVDAK and integrin beta-6 ADCs overlap in solid tumors
- Whitehawk Therapeutics
PTK7 ADC in a recruiting Phase 1 solid-tumor trial
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Sutro Biopharma | $20.47 | −1.68% | $198.1M | — | — | 4.3 | −84.6% |
| Pfizer | $29.00 | −0.10% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Whitehawk Therapeutics | $4.64 | −1.59% | $268.5M | — | — | — | — |
| Median | 38.3 | 10.4 | 2.6 | +2.6% |